We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hormone Shows Promise for Treating Celiac Disease

By Biotechdaily staff writers
Posted on 27 Feb 2003
Results from a recent study suggest that a synthetic form of alpha-melanocyte-stimulating hormone (alpha-MSH) has an anti-inflammatory effect on celiac mucosa and may lead to the first medical treatment for celiac disease. More...
The study appeared in the February 20, 2003, issue of NeuroImmunoModulation.

Alpha-MSH is a naturally occurring molecule that modulates inflammatory and immune responses. Data confirming the presence of alpha-MSH in celiac mucosa suggest the presence of a local reaction of the molecule to control the inflammatory response elicited by gliadin. Gliadin is the subfraction of gluten that acts as a toxin in people with celiac disease, causing an immune reaction and resulting in damage to the small intestine.

"Our research suggests that locally produced alpha-SH modulates inflammation and perhaps limits epithelial damage in patients with celiac disease,” said James M. Lipton, Ph.D., study investigator and chief scientific officer of Zengen, Inc. (Woodland Hills, CA, USA). "We are particularly excited by these findings as these data, coupled with abundant evidence of the anti-inflammatory and anti-infective activity of Zengen's novel molecules based on alpha-MSH, further validate our research and development efforts in numerous areas, including celiac disease.”





Related Links:
Zengen

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Clinical Informatics Platform
CLARION™
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: An elevated neutrophil-to-lymphocyte ratio (NLR), a rato easily obtained from a routine blood count, was associated with both short- and long-term Alzheimer’s risk (photo credit: 123RF)

Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk

Alzheimer’s disease and related dementias develop over years, making it difficult to identify at-risk patients before symptoms appear. Clinicians therefore need widely available laboratory markers that... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.